Table 1.

Efficacy outcomes at week 52

	FIL 200 mg + MTX (n = 416)	FIL 100 mg + MTX (n = 207)	FIL 200 mg (n = 210)	MTX (n = 416)
ACR20, %	75.0^***	73.4^**	74.8^***	61.8
ACR50, %	62.3^***	59.4^**	61.4^**	48.3
ACR70, %	47.8^***	40.1^*	45.2^***	29.8
mTSS^a	0.21^***	0.27^*	0.23^**	0.74
HAQ-DI^b	−1.00^***	−0.97	−0.95^*	−0.88

^aLeast-squares mean change from baseline.
^bMean change from baseline.
^*, p <0.05; ^**, p <0.01; ^***, p <0.001 vs MTX alone; not adjusted for multiplicity.
FIL, filgotinib; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate.